Salvatore Savatta, MD
Psychiatry · Elizabeth, NJNPI 1164670717
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $67,970 of the $76,247 with a category attached, or 89.1%. 19 manufacturers reported payments, led by AbbVie at 54.6% of the total. Reporting peaked in 2020 at $13,832 and has fallen 50.4% since, to $6,867 in 2025. Among psychiatry clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 576 payments — averaging $132.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$42K
- Otsuka America Pharmaceutical, Inc.$24K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$7K
- Johnson & Johnson$844
- Neurocrine Biosciences, Inc.$622
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$514
- plus $2K from 13 others
What the payments were for
- Speaking & faculty fees$67,97089%
- Travel & lodging$8521%
- Food & beverage$7,2349%
- Education$1920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 175 | $41,652 |
| Otsuka America Pharmaceutical, Inc. | 88 | $23,555 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 10 | $7,358 |
| Johnson & Johnson | 61 | $844 |
| Neurocrine Biosciences, Inc. | 68 | $622 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $514 |
| Alkermes, Inc. | 26 | $338 |
| Teva Pharmaceuticals USA, Inc. | 27 | $264 |
| E.r. Squibb & Sons, L.L.C. | 26 | $241 |
| Axsome Therapeutics, Inc. | 20 | $220 |
| Supernus Pharmaceuticals, Inc. | 9 | $134 |
| Almatica Pharma LLC | 8 | $116 |
| Lundbeck LLC | 5 | $93 |
| Neos Therapeutics, LP | 4 | $78 |
| Vanda Pharmaceuticals Inc. | 4 | $63 |
| Sunovion Pharmaceuticals Inc. | 5 | $62 |
| Indivior Inc. | 3 | $43 |
| Tris Pharma Inc | 2 | $34 |
| Bausch Health US, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$39,773
- ABILIFY MAINTENA$14,992
- REXULTI$760
- SPRAVATO$110
How this compares
$76,247 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 35 | $251,060 |
| IngrezzaValbenazine Tosylate | 22 | $184,351 |
| VraylarCariprazine Hcl | 29 | $43,548 |
| RexultiBrexpiprazole | 16 | $32,802 |
| Abilify MaintenaAripiprazole | 11 | $25,360 |
| EmsamSelegiline | 12 | $24,306 |
| BelsomraSuvorexant | 31 | $16,182 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $11,345 |
| Bupropion XlBupropion Hcl | 120 | $4,036 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 98 | $3,178 |
| Aripiprazole | 72 | $2,734 |
| Clonazepam | 236 | $2,307 |
| Duloxetine Hcl | 112 | $2,182 |
| Buspirone Hcl | 104 | $1,730 |
| Quetiapine Fumarate | 106 | $1,641 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $264 | $251,06035 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $622 | $184,35122 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $23,555 | $58,16227 claims |
| AbbVieVraylar | $41,652 | $43,54829 claims |
| Axsome Therapeutics, Inc.Auvelity | $220 | $11,34511 claims |
| Almatica Pharma LLCSertraline Hcl | $116 | $1,078104 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in Elizabeth
- Raed OdehElizabeth$19K
- Jesus PenaElizabeth$8K
- Marc CantillonLivingston$522K
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
- Leon RosenbergCherry Hill$257K
- Lloyd AlceraMarlton$187K
- Gary SmallHackensack$170K
- Shankar SrinivasanParsippany$155K
- Matthew PiteraToms River$153K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.